Harness, Scaffold, and the AI Agent Terms Worth Getting Right
More from the blog
Safety for Whom? Refusing the Right Subset of a Topic, Not the Whole Topic
GPT-Lab
· gpt-lab.eu
Sep 3, 2026
Adaptive AI Agents in Construction Workflows
Adaptive AI agents can help make BIM data more machine-readable by navigating IFC models, interpreting inconsistent information, and mapping it to defined standards. In this blog, Alok Rawat shares findings from a real-world pilot in construction workflows. The post Adaptive AI Agents in Construction Workflows appeared first on GPT-Lab.
Related papers
mRNABERT: advancing mRNA sequence design with a universal language model and comprehensive dataset
The authors develop mRNABERT, a foundational AI model that designs entire mRNA sequences and demonstrates superior performance across comprehensive benchmarks, which signifies a substantial leap forward in mRNA research and therapeutic development.
Computational and AI-Driven Ecosystem for Structure-Based Covalent Drug Discovery.
This Account describes a computational and AI-driven ecosystem for structure-based covalent drug discovery and dives into a suite of cutting-edge, AI-driven computational methods, exploring the potential of deep learning in tasks such as molecular docking, covalent binding site prediction, and lead optimization.
Facilitating structure-based drug discovery with an artificial intelligence-driven virtual screening platform.
The Comprehensive VS Platform with AI Engine (CVSP-AIE) for drug discovery from compound libraries integrates three AI models: KarmaDock, a fast docking model that directly updates atomic coordinates; CarsiDock, an accurate docking model that predicts protein-ligand distances and reconstructs binding poses; and RTMScore, an accurate scoring model that learns residue-atom distance distributions for affinity prediction.
AI-driven PROTAC design overcomes oncogenic resilience by eliminating the CLIP1-LTK fusion protein.
The AI-guided development of a first-in-class proteolysis-targeting chimera (PROTAC) designed to selectively degrade the CLIP1-LTK fusion protein is reported, providing a promising therapeutic strategy for overcoming acquired resistance in kinase-driven cancers.